🔎 Trials Near Me

ホーム › 悪性黒色腫 › テネシー

テネシーにおける悪性黒色腫の臨床試験

テネシー内の拠点で、悪性黒色腫に関する40件の研究が参加者を募集しています。

テネシー内の都市

公式研究テキスト(英語)

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

  • Sarah Cannon Research Institute, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07751042

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • SCRI Oncology Partners, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478

A Study of BI 3810944 in Patients With Advanced Cancer

  • Tennessee Oncology, PLLC - Elliston Place Plaza DDU, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07224425

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

  • Sarah Cannon Research Institute- Pharmacy, Nashville
  • SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07519655

DESTINY-PANTUMOUR04

  • Research Site, Nashville
被験者募集中観察研究
18歳〜130歳 · 全性別 · 2026/09/25更新 · NCT07124000

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  • Tennessee Oncology - Chattanooga, Chattanooga
  • University of Tennessee Medical Center, Knoxville
  • Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
  • 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06246916

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

  • Baptist Cancer Center, Bartlett
  • SCRI Oncology Partners, Nashville
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT05727904

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

  • East Tennessee Childrens Hospital, Knoxville
  • Saint Jude Children's Research Hospital, Memphis
被験者募集中第2相
25歳以下 · 全性別 · 2026/09/24更新 · NCT07621614

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Vanderbilt University Medical Center, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379

Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

  • Vanderbilt University/Ingram Cancer Center, Nashville
被験者募集中第3相
75歳以上 · 全性別 · 2026/09/24更新 · NCT07068074

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

  • Sarah Cannon Research Institute, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05267626

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

  • Sarah Cannon Research Institute, Nashville
被験者募集中第1相
18歳〜80歳 · 全性別 · 2026/09/18更新 · NCT06398418

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

  • Sarah Cannon Research Institute Oncology Partners, Nashville
  • Vanderbilt-Ingram Cancer Institute, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07287917

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

  • Sarah Cannon Research Institute-Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT04913285

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Saint Jude Children's Research Hospital, Memphis
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119

Project: Every Child for Younger Patients With Cancer

  • T C Thompson Children's Hospital, Chattanooga
  • East Tennessee Childrens Hospital, Knoxville
  • Saint Jude Children's Research Hospital, Memphis
  • 他2件
被験者募集中観察研究
25歳以下 · 全性別 · 2026/08/25更新 · NCT02402244

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  • Vanderbilt University Medical Center, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT04895709

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

  • Tennessee Oncology, PLLC, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/14更新 · NCT06425926

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Erlanger Health, Inc, Chattanooga
  • The West Clinic, Germantown
  • SCRI Oncology Partners, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06330064

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

  • Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/28更新 · NCT06150664

Familial Investigations of Childhood Cancer Predisposition

  • St. Jude Children's Research Hospital, Memphis
被験者募集中観察研究
全年齢 · 全性別 · 2026/06/17更新 · NCT03050268

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

  • Sarah Cannon Research Institute, Nashville
被験者募集中第1/2相
18歳〜70歳 · 全性別 · 2026/06/15更新 · NCT06940739

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

  • The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/08更新 · NCT03947385

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

  • St. Jude Children's Research Hospital, Memphis
被験者募集中第1相
21歳以下 · 全性別 · 2026/05/19更新 · NCT04897321

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

  • Tennessee Oncology, Chattanooga
  • Sarah Cannon Research Institute, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/15更新 · NCT05379985

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

  • Vanderbilt-Ingram Cancer Center, Nashville
被験者募集中
18歳以上 · 全性別 · 2026/05/06更新 · NCT07555210

Neoadjuvant Darovasertib in Primary Uveal Melanoma

  • SCRI Oncology Partners, Nashville
  • Vanderbilt Eye Institute, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/06更新 · NCT07015190

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

  • SCRI Oncology Partners, Nashville
  • Vanderbilt-Ingram Cancer Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/20更新 · NCT06326411

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

  • The West Clinic, PLLC dba West Cancer Center, Germantown
  • University of Tennessee Medical Center, Knoxville
  • Sarah Cannon Research Institute, Nashville
  • 他1件
被験者募集中第2/3相
全年齢 · 全性別 · 2026/04/02更新 · NCT06581406

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
  • Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
  • Baptist Memorial Hospital for Women, Memphis
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

  • University of Tennessee Medical Center, Knoxville
被験者募集中第3相
18歳以上 · 全性別 · 2026/02/25更新 · NCT05549297

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

  • Vanderbilt-Ingram Cancer Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT04903119

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

  • Research Site 136, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/21更新 · NCT05914116

Molecular Analysis of Childhood and Adolescent Melanocytic Lesions

  • St. Jude Children's Research Hospital, Memphis
被験者募集中観察研究
18歳以下 · 全性別 · 2025/11/10更新 · NCT02775643

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Memphis
  • Massive Bio SYNERGY-AI site, Nashville
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774

Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

  • Vanderbitl-Ingram Cancer Center, Nashville
被験者募集中観察研究
18歳以上 · 全性別 · 2025/09/19更新 · NCT01205815

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

  • Sarah Cannon Research Institute, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/05/18更新 · NCT05970497

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

  • Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/02/13更新 · NCT05669430

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。